Adaptive Sample Size Modification in Clinical Trials: Start Small then Ask for More?

Christopher Jennison
Department of Mathematical Sciences, University of Bath, UK
http://people.bath.ac.uk/mascj

Bruce Turnbull
Department of Statistical Science, Cornell University
http://www.orie.cornell.edu/~bruce

DIA Adaptive Design Scientific Working Group

KOL lecture series
8 February 2019
Outline of talk

1. Choosing the sample size for a trial
   Group sequential and adaptive approaches

2. An example from Mehta & Pocock (SIM, 2011)
   (i) Mehta & Pocock’s “promising zone” design
   (ii) Improving designs in Mehta & Pocock’s framework
        (Jennison & Turnbull, SIM, 2015)
   (iii) Relation to delayed response GSTs (Hampson & Jennison, JRSS B, 2013)
   (iv) Convergence of ideas: Hsiao, Liu & Mehta,
        (Biometrical Journal, 2018)

3. Conclusions
1. Choosing the sample size for a clinical trial

You might think this would be a simple question . . .

Let $\theta$ denote the effect size of a new treatment, e.g., the difference in mean response between the new treatment and the control.

Sample size is determined by:

Type I error rate $\alpha$, and

Treatment effect size $\theta = \Delta$ at which power $1 - \beta$ is to be achieved.

Dispute may arise over the choice of $\Delta$.

Should investigators use:

The minimum effect of interest $\Delta_1$, or

The anticipated effect size $\Delta_2$?
Choosing the sample size for a clinical trial

Power curves for designs with sample sizes of 500 and 1000.

With 1000 subjects, there is good power at the minimum clinically significant effect, $\Delta_1$.

With only 500 subjects, a high power is achieved at the more optimistic $\Delta_2$.

If $\theta = \Delta_2$, a sample size of 1000 is unnecessarily high.
In designing a clinical trial, we aim to

*Protect the type I error rate,*

*Achieve sufficient power,*

*Use as small a sample size as possible.*

We can use **Group Sequential** or **Adaptive** designs to achieve desired error rates with a small average sample size.
A typical boundary for a one-sided test, expressed in terms of standardised test statistics $Z_1, \ldots, Z_K$, has the form:

Crossing the upper boundary leads to early stopping for a positive outcome, rejecting $H_0$: $\theta \leq 0$ in favour of $\theta > 0$.

Crossing the lower boundary implies stopping for “futility” with acceptance of $H_0$. 

Chris Jennison and Bruce Turnbull
Error spending group sequential tests

Let $\mathcal{I}_k = \{\text{Var}(\hat{\theta}_k)\}^{-1}$ denote the information for $\theta$ at analysis $k$.

When the sequence $\mathcal{I}_1, \mathcal{I}_2, \ldots$ is unpredictable, a group sequential design must adapt to observed information levels.

Lan & DeMets (Biometrika, 1983) introduced “error spending” tests of $H_0: \theta = 0$ against $\theta \neq 0$.

**Maximum information design** with error spending function $f(\mathcal{I})$.

The boundary at analysis $k$ is set to give cumulative type I error probability $f(\mathcal{I}_k)$. 
One-sided error spending tests

For a one-sided test of \( H_0: \theta \leq 0 \) against \( \theta > 0 \) with

- Type I error probability \( \alpha \) at \( \theta = 0 \),
- Type II error probability \( \beta \) at \( \theta = \delta \),

we need two error spending functions.

Type I error probability \( \alpha \) is spent according to the function \( f(I) \), and type II error probability \( \beta \) according to \( g(I) \).
At analysis $k$: With observed information $\mathcal{I}_k$

We find $a_k$ and $b_k$ to satisfy

$$P_{\theta=0}\{a_1 < Z_1 < b_1, \ldots, a_{k-1} < Z_{k-1} < b_{k-1}, Z_k > b_k\} = f(\mathcal{I}_k) - f(\mathcal{I}_{k-1}),$$

and

$$P_{\theta=\delta}\{a_1 < Z_1 < b_1, \ldots, a_{k-1} < Z_{k-1} < b_{k-1}, Z_k < a_k\} = g(\mathcal{I}_k) - g(\mathcal{I}_{k-1}).$$

---

Chris Jennison and Bruce Turnbull

Start Small then Ask for More?
Benefits of group sequential testing

Properties of one-sided tests with binding futility boundaries, 
mimising \( \{E_0(I) + E_{\delta}(I)\}/2 \) for \( K \) equally sized groups, 
\( \alpha = 0.025 \), power \( 1 - \beta = 0.9 \) at \( \theta = \delta \), and \( \mathcal{I}_{max} = R \mathcal{I}_{fix} \).

Minimum values of \( \{E_0(I) + E_{\delta}(I)\}/2 \), as a percentage of \( \mathcal{I}_{fix} \)

<table>
<thead>
<tr>
<th>( K )</th>
<th>1.01</th>
<th>1.05</th>
<th>1.1</th>
<th>1.2</th>
<th>1.3</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>80.8</td>
<td>74.7</td>
<td>73.2</td>
<td>73.7</td>
<td>75.8</td>
</tr>
<tr>
<td>3</td>
<td>76.2</td>
<td>69.3</td>
<td>66.6</td>
<td>65.1</td>
<td>65.2</td>
</tr>
<tr>
<td>5</td>
<td>72.2</td>
<td>65.2</td>
<td>62.2</td>
<td>59.8</td>
<td>59.0</td>
</tr>
<tr>
<td>10</td>
<td>69.2</td>
<td>62.2</td>
<td>59.0</td>
<td>56.3</td>
<td>55.1</td>
</tr>
<tr>
<td>20</td>
<td>67.8</td>
<td>60.6</td>
<td>57.5</td>
<td>54.6</td>
<td>53.3</td>
</tr>
</tbody>
</table>

Here, \( \mathcal{I}_{fix} \) is the information required for a fixed sample size test 
to achieve type I error rate \( \alpha \) and power \( 1 - \beta \) at \( \theta = \delta \).
Suppose we run a clinical trial adaptively in two stages:

Set the design of Stage 1,

Conduct Stage 1,

Analyse results from Stage 1,

Set the design of Stage 2, choosing the sample size based on Stage 1 results,

Conduct Stage 2,

Analyse the results from Stage 2.

We need a way to test the null hypothesis $H_0: \theta \leq 0$ that properly protects the type I error rate — a combination test can do this.
Before the trial commences, define the null hypothesis.

Let $\theta$ denote the treatment effect vs control for a specified form of the treatment, patient population and endpoint.

We test $H_0: \theta \leq 0$ against $\theta > 0$, with type I error rate $\alpha$ at $\theta = 0$.

Define one-sided P-values $P_1$ and $P_2$ from hypothesis tests of $H_0$ based on Stage 1 and Stage 2 data, respectively.

**Under $\theta = 0$**

$P_1 \sim U(0, 1)$.

Conditionally on all Stage 1 data and the Stage 2 design, $P_2 \sim U(0, 1)$.

Hence, $P_1$ and $P_2$ are independent $U(0, 1)$ variates.
The inverse normal combination test

Initial design

Specify the inverse normal test for null hypothesis $H_0$, with weights $w_1$ and $w_2$ where $w_1^2 + w_2^2 = 1$.

Design Stage 1, fixing sample size and test statistic.

Stage 1

Observe the one-sided P-value, $P_1$, based on Stage 1 data.

Compute $Z_1 = \Phi^{-1}(1 - P_1)$.

Design Stage 2 in the light of Stage 1 data.

Stage 2

Observe the P-value, $P_2$, based only on Stage 2 data.

Compute $Z_2 = \Phi^{-1}(1 - P_2)$.

NB Under $\theta = 0$, $Z_1 \sim N(0, 1)$, $Z_2 \sim N(0, 1)$, independent.
The inverse normal combination test

Under $\theta = 0$, $Z_1$ and $Z_2$ are independent $N(0, 1)$, so

$$w_1 Z_1 + w_2 Z_2 \sim N(0, 1).$$

Hence, for an overall one-sided test with type I error rate $\alpha$, we reject $H_0$ if

$$w_1 Z_1 + w_2 Z_2 > \Phi^{-1}(1 - \alpha).$$

If $\theta < 0$, then $Z_1$ and $Z_2$ are stochastically smaller than $N(0, 1)$ random variables and the type I error rate is less than $\alpha$. If $w_1$ and $w_2$ are proportional to the square roots of the Stage 1 and Stage 2 sample sizes then $w_1 Z_1 + w_2 Z_2$ is the standard $Z$-statistic based on the data at the end of Stage 2.

However, it is crucial that initially specified weights, $w_1$ and $w_2$, are used in the final test.
Adaptive sample size modification

The general adaptive framework allows investigators to choose a moderately large sample size initially, then

If interim data are in line with original assumptions, the trial continues as planned,

If interim data suggest the treatment effect is lower than expected, the final sample size can be increased.

In a two stage design, as outlined in previous slides, a pre-specified combination test protects the type I error rate at level $\alpha$.

Multi-stage adaptive designs are also possible:

Lehmacher & Wassmer (*Biometrics*, 1999) describe a multi-stage version of the combination test.

Cui, Hung & Wang (*Biometrics*, 1999) show how to increase group sizes in a group sequential design.
In designing a clinical trial, with a given type I error rate, adequate power, and as small a sample size as possible:

**Adaptive** designs have the form:

*Start with a fixed sample size design,*

*Examine interim data,*

*Add observations to improve power where most appropriate.*

**Group Sequential** designs require one to:

*Specify the desired type I error and power function,*

*Set maximum sample size a little more than the fixed sample size,*

*Stop the trial early if data support this.*
All designs, *including adaptive designs*, have overall power curves.

Designs with similar power curves can be compared in terms of their average sample size functions, $E_\theta(N)$.

Even if there is uncertainty about the likely treatment effect, investigators should be able to specify the values of $\theta$ under which early stopping is most desirable.
Adaptive or group sequential designs?

Jennison & Turnbull have studied optimal versions of adaptive and non-adaptive sequential designs (e.g., *Statist. in Med.*, 2003 and 2006; *Biometrika*, 2006).

The set of group sequential tests (GSTs) is a subset of the set of adaptive designs (which can adapt group sizes to observed responses).

Adaptive designs are, at best, a little more efficient than GSTs with the same number of analyses, reducing average sample size by 1% or 2% for the same power.

Many published adaptive designs are considerably less efficient than a well chosen GST.

And advice is available on how to create good group sequential designs:
Re-visiting the *Group Sequential vs Adaptive* question

The paper by Mehta & Pocock (*Statistics in Medicine*, 2011)

“Adaptive increase in sample size when interim results are promising: A practical guide with examples”

has re-opened this question.

Conclusions of Mehta & Pocock (MP) are counter to the findings we have reported.

**An important feature:**

In MP’s first example, response is measured some time after treatment.

Thus, at an interim analysis, many patients have been treated but are yet to produce a response.

Delayed responses are common — and not easily dealt with by standard GSTs.
MP’s Example 1 concerns a Phase 3 trial of a new treatment for schizophrenia, comparing the new drug to an active control. The efficacy endpoint is improvement in the Negative Symptoms Assessment score from baseline to week 26.

Responses are

\[ Y_{Bi} \sim N(\mu_B, \sigma^2), \quad i = 1, 2, \ldots, \text{ on the new treatment}, \]

\[ Y_{Ai} \sim N(\mu_A, \sigma^2), \quad i = 1, 2, \ldots, \text{ on the control arm}, \]

where \( \sigma^2 = 7.5^2 \).

The treatment effect is

\[ \theta = \mu_B - \mu_A. \]

and we estimate \( \theta \) by

\[ \hat{\theta} = \hat{\mu}_B - \hat{\mu}_A = \bar{Y}_B - \bar{Y}_A. \]
The initial plan is for a total of $n_2 = 442$ patients, 221 on each treatment.

In testing $H_0: \theta \leq 0$ vs $\theta > 0$ at the final analysis, we reject $H_0$ if

$$Z_2 = \frac{\hat{\theta}(n_2)}{\sqrt{4\sigma^2/n_2}} > 1.96.$$

This design and analysis gives type I error rate 0.025 and power 0.8 at $\theta = 2$.

Higher power, e.g., power 0.8 at $\theta = 1.6$, would be desirable.

But, the sponsors will only increase sample size if interim results are “promising”.

An interim analysis is planned after observing $n_1 = 208$ responses.
Increasing the sample size

At the interim analysis with $n_1 = 208$ observed responses, the estimated treatment effect is

$$\hat{\theta}_1(n_1) = \bar{Y}_B(n_1) - \bar{Y}_A(n_1)$$

and

$$Z_1 = \frac{\hat{\theta}_1(n_1)}{\sqrt{\frac{4\sigma^2}{n_1}}}.$$

At this analysis, a further 208 subjects will have been treated for less than 26 weeks. Their responses will be observed in due course.

As recruitment continues, we use the value of $Z_1$ in choosing a new total sample size — between the original figure of 442 and a maximum of 884.

In deciding whether to increase the sample size, MP consider conditional power of the original test with $n_2 = 442$ observations, given the observed value of $Z_1$. 
Increasing the sample size

Definition

The conditional power \( CP_\theta(z_1) \) is the probability the final test, with 442 observations, rejects \( H_0 \), given \( Z_1 = z_1 \) and effect size \( \theta \),

\[
CP_\theta(z_1) = P_\theta\{Z_2 > 1.96 \mid Z_1 = z_1\}.
\]

MP’s design is based on **conditional power under \( \theta = \hat{\theta}_1 \)**.

They divide the range of \( z_1 \) into three regions:

- **Favourable** \( CP_{\hat{\theta}_1}(z_1) \geq 0.8 \)  \hspace{1cm} *Continue to \( n_2 = 442 \),*

- **Promising** \( 0.365 \leq CP_{\hat{\theta}_1}(z_1) < 0.8 \)  \hspace{1cm} *Increase \( n_2 \),*

- **Unfavourable** \( CP_{\hat{\theta}_1}(z_1) < 0.365 \)  \hspace{1cm} *Continue to \( n_2 = 442 \).*

When increasing sample size in the promising zone, the final test of \( H_0 \) must protect the type I error rate at level \( \alpha \).
The Chen, DeMets & Lan method

References:


Suppose at interim analysis 1, the final sample size is increased to $n_2^* > n_2$ and, naively, $H_0$ is rejected if

$$Z_2(n_2^*) = \frac{\hat{\theta}(n_2^*)}{\sqrt{4\sigma^2/n_2^*}} > 1.96.$$ 

Chen, DeMets & Lan (CDL) show that if $n_2$ is only increased when $CP_{\hat{\theta}_1}(z_1) > 0.5$, then the type I error probability will not increase.

(In general, changes to sample size may increase or decrease the type I error rate.)
Gao’s extension of the CDL method

Gao et al. extended the CDL method to lower values of $\hat{\theta}_1$, as long as a sufficiently high value is chosen for the final sample size, $n^*_2$.

With an upper limit of $n^*_2 = 884$, the final sample sizes permitted by the CDL+Gao approach are as shown in the figure.

Now, $n_2$ can be increased when $CP_{\hat{\theta}_1}(z_1)$ is as low as 0.365.
The MP “Promising Zone” design

In their “promising zone”, MP increase $n_2$ to achieve conditional power 0.8 under $\theta = \theta_1$, truncating this value to 884 if it is larger than that.

Comparison with the distribution of $\hat{\theta}_1$ under $\theta = 1.6$ shows that increases in $n_2$ occur in a region of quite small probability.

The distribution of $\hat{\theta}_1$ under other values of $\theta$ is shifted but has the same variance.
The increase in $n_2$ in the “promising zone” has increased the power curve a little.

![Graph showing power curve]

Given the limited range of values of $\hat{\theta}_1$ for which $n_2$ is increased, only a small improvement in power can be expected.

Although it was stated that power 0.8 at $\theta = 1.6$ would be desirable, power at this effect size has only risen from 0.61 to 0.66.
Properties of the MP design

The cost of higher power is an increase in expected sample size.

Aiming for higher conditional power under $\theta = \hat{\theta}_1$ or raising the sample size beyond 884 would give a small increase in power at the cost of a large increase in $E(N)$. 
Alternatives to the MP design

Suppose we are satisfied with the overall power function attained by MP’s design: the same power can be achieved by other designs.

A fixed sample design

Emerson et al. (*Statistics in Medicine*, 2011) note that the same power is achieved by a fixed sample size study with 490 subjects.

This is an attractive option since $E_\theta(N)$ for the MP design is greater than 490 for effect sizes $\theta$ between 0.8 and 2.0.

NB: There is more to sample size distribution than $E_\theta(N)$

High variance in $N$ is usually regarded as undesirable, so the wide variation in $N$ for the MP design is a negative feature.

Perhaps variation in $N$ is viewed more positively when investors in a small bio-tech company are thinking of adding resource to a study when it is most helpful?
A group sequential test

Despite the delayed response, we can still consider a group sequential design.

Suppose an interim analysis takes place after 208 observed responses. If the trial stops at this analysis, we take the sample size as 416, counting all subjects treated thus far — even though only 208 have provided a response.

We apply an error spending design in the \( \rho \)-family (JT, Ch. 7):

At analysis 1 after 208 responses

- If \( Z_1 \geq 2.54 \) Stop, reject \( H_0 \)
- If \( Z_1 \leq 0.12 \) Stop, accept \( H_0 \)
- If \( 0.12 < Z_1 < 2.54 \) Continue

At analysis 2 after 514 responses

- If \( Z_2 \geq 2.00 \) Reject \( H_0 \)
- If \( Z_2 < 2.00 \) Accept \( H_0 \)
Sample size rules for MP, fixed and group seq. designs

Sample size for the MP design varies between 442 and 884.

The fixed sample size design has 490 observations.

The group sequential test stops with a sample size of 416 or 514. Since $514 = 490 \times 1.05$, it has an “inflation factor” of $R = 1.05$. 

![Graph showing the sample size variation for different designs](image-url)
All three designs have essentially the same power curve.

It is clearly possible to improve on the MP design’s $E_\theta(N)$ curve.

NB, Mehta & Pocock discuss two-stage group sequential designs but they only present an example with much higher power (and, thus, higher sample size).
Can we improve the design within the MP framework?

Why does the MP design have high $E_\theta(N)$ for its achieved power?

Mehta & Pocock describe their method as adding observations in situations where they will do the most good:

This seems a good idea, but the results are not so great,

Can we work out how to do this effectively?

Reference: Jennison & Turnbull (*SiM*, 2015)

Adaptive sample size modification in clinical trials: start small then ask for more?
Continuing with MP’s example, we retain the basic elements of the MP design.

The interim analysis takes place after 208 observed responses.

A final sample size \( n^*_2 \) is chosen based on \( \hat{\theta}_1 \) (or equivalently \( Z_1 \)).

Values of \( n^*_2 \in [442, 884] \) that satisfy the CDL+Gao conditions are allowed.

At the final analysis, we reject \( H_0 \) if \( Z_2 > 1.96 \), where \( Z_2 \) is calculated without adjustment for adaptation.
We shall assess the value of an increase in sample size in terms of the conditional power that it achieves.

Suppose $Z_1 = z_1$ and we are considering a final sample size $n_2^*$ with

$$Z_2(n_2^*) = \frac{\hat{\theta}(n_2)}{\sqrt{4\sigma^2/n_2}}$$

and conditional power under $\theta = \tilde{\theta}$

$$CP_{\tilde{\theta}}(z_1, n_2^*) = P_{\tilde{\theta}}\{Z_2(n_2^*) > 1.96 \mid Z_1 = z_1\}.$$

Setting $\gamma$ as a “rate of exchange” between sample size and power, we choose $n_2^*$ to optimise a combined objective

$$CP_{\tilde{\theta}}(z_1, n_2^*) - \gamma(n_2^* - 442).$$

We shall do this taking $\hat{\theta} = 1.6$, a value where we wish to “buy” additional power.
An overall optimality property

The rule that maximises \( CP_{\tilde{\theta}}(z_1, n_2^*(z_1)) - \gamma n_2^*(z_1) \) for every \( z_1 \) also maximises, unconditionally,

\[
P_{\theta=\tilde{\theta}}(\text{Reject } H_0) - \gamma E_{\tilde{\theta}}(N).
\]

This can be seen by writing \( P_{\theta=\tilde{\theta}}(\text{Reject } H_0) - \gamma E_{\tilde{\theta}}(N) \) as

\[
\int \{ CP_{\tilde{\theta}}(z_1, n_2^*(z_1)) - \gamma n_2^*(z_1) \} f_{\tilde{\theta}}(z_1) \, dz_1,
\]

where \( f_{\tilde{\theta}}(z_1) \) denotes the density of \( Z_1 \) under \( \theta = \tilde{\theta} \), and noting that we have minimised the integrand for each \( z_1 \).

We set \( \gamma = 0.14/(4 \sigma^2) \) to achieve the power of the MP design.

So, the resulting procedure will have minimum possible \( E_{\theta=1.6}(N) \) among all designs following the CDL+Gao framework that achieve power 0.658 at \( \theta = 1.6 \).
The objective $CP_{\tilde{\theta}}(z_1, n_2^*) - \gamma(n_2^* - 442)$ has a maximum at $n_2^* = 654$.

This value is similar to MP’s choice of $n_2^*$ when $\hat{\theta}_1 = 1.5$. 
Plots of conditional power and combined objective function

Plots for $\tilde{\theta} = 1.6$, $\gamma = 0.14/(4\sigma^2)$ and $\hat{\theta}_1 = 1.3$

In this case, the conditional power curve is steeper and the optimum occurs at a higher $n_2^*$. Now, $CP_{\tilde{\theta}}(z_1, n_2^*) - \gamma(n_2^* - 442)$ is maximised at $n_2^* = 707$. MP’s design takes the maximum permitted value of $n_2^* = 884$. 
Optimal sample size rule for $\tilde{\theta} = 1.6$, $\gamma = 0.14/(4\sigma^2)$

This rule gives power 0.658 at $\theta = 1.6$, the same as the MP design.

Decisions about sample size are based on a consistent comparison of the higher power and the cost of additional observations.

As $\hat{\theta}_1$ decreases, sample size increases less steeply than for the MP design.
With the type I error rate fixed at 0.025, matching the MP design’s power at one value of $\theta$ will match the whole power curve.

Our optimised design has the same power curve as the MP design and lower $E_\theta(N)$ (just about) at all $\theta$ values.

The reductions in $E_\theta(N)$ are modest — but given the optimality property of the sampling rule in the Mehta & Pocock framework, this is as good as it gets.
Further efficiency gains

Our new, optimised procedure still has higher $E_{\theta}(N)$ than the two-stage GST that ignores (but is charged for) pipeline data.

Shapes of optimised sample size rules suggest it would help to increase $n_2^*$ at lower values of $\hat{\theta}_1$ — but this is not allowed in the CDL+Gao framework.

If we use a **Combination Test**, such adaptations are permissible.
Optimal sample size rule for a combination test design

We follow our previous strategy in this new framework and set $n_2^*$ to maximise $CP_{\tilde{\theta}}(z_1, n_2^*) - \gamma(n_2^* - 442)$, where $\tilde{\theta} = 1.6$.

The design with this sample size rule for $\gamma = 0.25/(4\sigma^2)$ matches the MP test’s power of 0.658 at $\theta = 1.6$.

Shapes of optimised sample size rules are very different from the MP design — the best opportunities for investing additional resource are not in Mehta & Pocock’s “promising zone”.
When using a combination test, we can increase sample size for $\hat{\theta}_1$ below the CDL+Gao region.

This leads to a useful reduction in $E_\theta(N)$ at $\theta = 1.6$. 
Further extensions

1. We can allow recruitment to terminate at the interim analysis, so the minimum sample size is $n_2 = 416$, rather than 442.

2. We can use a general combination test or, equivalently, a general conditional type I error function (Proschan & Hunsberger, *Biometrics*, 1995).

3. We can minimise other average sample size criteria, such as a weighted sum or integral

$$\sum_i w_i E_{\theta_i}(N) \quad \text{or} \quad \int w(\theta) E_{\theta_i}(N) \, d\theta.$$ 

The resulting two-stage designs deal neatly with the “pipeline” subjects arising when there is a delayed response.

For the chosen criteria, they will give the best possible sampling and decision rules with $n_1 = 208$ and $n_2$ in the range 416 to 884.
General sampling rule, early termination of recruitment

We have followed (1) and (2) above in minimising $E_{\theta=1.6}(N)$.

Sample size rule

Reductions in $E_{\theta}(N)$ are mostly due to (1), which allows $n_2$ to be limited to 416.

The highest final sample sizes arise at values of $\hat{\theta}_1$ below MP’s “promising zone”.

E_{\theta}(N) curves

Hampson & Jennison have extended methodology for group sequential tests to handle a delayed response.

Their “Delayed Response GSTs” allow any number of interim analyses and can be optimised for specified criteria.

Applying this approach in the case of just 2 analyses:

Either recruitment stops at analysis 1 and the final analysis occurs when all pipeline subjects have been observed,

Or, an additional group of subjects is recruited and the final analysis has pipeline subjects plus these new subjects.

Thus, we have a special case of the designs we have been developing where only two values of $n_2$ are possible.
Delayed Response GST for the MP example

Optimising a DR GST to minimise $E_{\theta=1.6}(N)$ while matching the power of the MP design gives the sample size rule shown below.

The sampling rule approximates that of the general adaptive method, but with a step function rather than a continuous sample size function.
Properties of the optimal DR GST

The optimised DR GST has an almost identical $E_\theta(N)$ curve to the general rule that uses the continuum of possible sample sizes.

Thus, as Jennison & Turnbull (*Biometrika*, 2006) found for an immediate response, there is minimal benefit from fine-tuning the total sample size in response to interim data.
Hsiao et al. re-visited promising zone designs and used optimised versions of these designs to benchmark their proposals. Using our earlier notation, their proposed design is as follows:

**Constrained Promising Zone Design**

In the final analysis, use an inverse normal combination test. Set $n_2^*$ to maximise $CP_{\tilde{\theta}}(z_1, n_2^*)$, subject to

- $n \leq n_2^* \leq n_{max}$,
- $CP_{\tilde{\theta}}(z_1, n_2^*) \leq cp_{max}$,
- $CP_{\tilde{\theta}}(z_1, n_2^*) \geq cp_{min}$ if $n_2^* > n_2$.

(Note the use of $CP_{\tilde{\theta}}$ rather than $CP_{\tilde{\theta}_1}$.)

The third constraint ensures that sample size is only increased if conditional power can be raised to an acceptable level.
Hsiao et al. assessed their new design by comparing it with:

**Constrained Jennison-Turnbull Design**

In the final analysis, use an inverse normal combination test. Set $n_2^*$ to maximise $CP_\tilde{\theta}(z_1, n_2^*) - \gamma n_2^*$, subject to

$$n \leq n_2^* \leq n_{max},$$

$$CP_\tilde{\theta}(z_1, n_2^*) \geq cp_{min} \text{ if } n_2^* > n_2.$$

Again, sample size is only increased if conditional power can be raised to an “acceptable” level.

In their example, with an appropriate choice of $\gamma$, the two methods produce designs with almost identical power and expected sample size functions.
3. Conclusions

1. Traditional GSTs provide efficient trial designs.

2. We have considered MP’s “Promising Zone” designs and developed their idea of spending resources where they have the greatest benefit — and found more efficient adaptive designs.

3. A simple option for a 2-stage design is to

   (i) use an inverse normal combination test and

   (ii) optimise the second stage sample size to maximise conditional power at $\theta = \tilde{\theta}$ minus a penalty for sample size.

4. An extension of this method gives designs very similar to the “Delayed Response GSTs” of Hampson & Jennison (2013).

5. The above approach can be combined with constraints — such as the requirement for a certain probability of success if additional resources are to be committed to a trial.